Table 3 KEGG analysis (top 15 signaling pathways with the smallest p-values)
ID | Term | Count | P Value |
|---|---|---|---|
hsa05418 | Fluid shear stress and atherosclerosis | 30 | 1.85E-31 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 27 | 3.72E-31 |
hsa05417 | Lipid and atherosclerosis | 31 | 8.25E-27 |
hsa05161 | Hepatitis B | 22 | 2.16E-18 |
hsa05212 | Pancreatic cancer | 17 | 3.40E-18 |
hsa04657 | IL-17 signaling pathway | 18 | 6.37E-18 |
hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 23 | 7.40E-18 |
hsa05145 | Toxoplasmosis | 19 | 7.82E-18 |
hsa05163 | Human cytomegalovirus infection | 24 | 1.54E-17 |
hsa05142 | Chagas disease | 18 | 2.99E-17 |
hsa04668 | TNF signaling pathway | 18 | 2.38E-16 |
hsa05215 | Prostate cancer | 17 | 2.79E-16 |
hsa04931 | Insulin resistance | 17 | 1.85E-15 |
hsa05140 | Leishmaniasis | 15 | 3.45E-15 |
hsa05205 | Proteoglycans in cancer | 21 | 4.95E-15 |
hsa01522 | Endocrine resistance | 16 | 7.36E-15 |
hsa05225 | Hepatocellular carcinoma | 19 | 1.88E-14 |
hsa04659 | Th17 cell differentiation | 16 | 3.62E-14 |
hsa04066 | HIF-1 signaling pathway | 16 | 4.20E-14 |
hsa04932 | Non-alcoholic fatty liver disease | 18 | 6.21E-14 |